FinancialBuzz.com: The Potential Influence of Politics on Small Cap Companies

PR Newswire

NEW YORK, January 26, 2017 /PRNewswire/ --

The small-cap market is often overlooked. Yet under certain conditions small caps can be a good place to look if certain measures are taken. These are high-risk high-reward companies, therefore extensive due diligence is required. A small cap company with potential will have a record of consistent public filings and strong management. Often, the current political environment may also have an effect on small cap companies. For example, certain policies of a new presidential administration, like increasing tariffs or starting a trade war, will be beneficial for small companies, explained Hank Smith, chief investment officer at Haverford Trust. Such policies, "would favor small stocks, which are domestically orientated, at the expense of the multinationals that make up the S&P 500." He told MarketWatch. Cell MedX Corp. (OTCQB: CMXC), Pura Naturals Inc. (OTCQB: PNAT), Federal National Mortgage Association (OTCQB: FNMA), Paladin Energy Ltd (OTC: PALAF), PharmaCyte Inc. (OTCQB: PMCB)

The new presidential administration also promised to significantly reduce business regulations, which also may be beneficial for small companies, as they are less equipped to deal with regulations and the expenses that ensue. Bruce Bittles, chief investment strategist at Robert W. Baird & Co. said, "Small-caps have been punished by overregulation because it is harder for them to absorb the impact of the regulation... Large companies are better equipped to deal with increased client costs, legal expenses."

Cell MedX Corp. (OTCQB: CMXC) is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, high blood pressure.

Earlier this week Cell MedX Corp. announced that it has received an approval from Health Canada to commence its observational clinical trial in Canada. The company revealed that it will, "launch the observational clinical trial of its innovative and proprietary technology branded under the trade name eBalance. The intent of the Trial is to assess the impact of eBalance therapy as an adjunct treatment on HbA1c after three months of therapy in relation to the subject's baseline data and medical history. Additional objectives of the Trial will be to assess the effect of eBalance therapy on insulin resistance and sensitivity as well as on various complications caused by diabetes."

Chief Executive Officer and President of Cell MedX Corp. Frank McEnulty said in a statement, "I am very excited to receive the approval from Health Canada in that it allows us to further advance research of our eBalance technology as well as its effects on both diabetes and diabetic complications."

Pura Naturals Inc. (OTCQB: PNAT) launched a division focused on developing solutions using AirTech Foam technologies and allied products directed towards oil spill prevention and remediation in our waterways, known as the Pura Marine. Pura Marine is currently in negotiations with some of the largest marine oil transport companies in the United States and in addition is actively pursuing business in the trucking and oil sectors. "We are dedicated to focusing our proprietary technologies on industries and markets where we can provide better solutions for current challenges and unmet needs," said Derek Duhame, President of Pura Naturals, Inc.

Federal National Mortgage Association (OTCQB: FNMA) priced its first Multifamily DUS® REMIC in 2017 totaling $1.04 billion under its Fannie Mae Guaranteed Multifamily Structures program on January 18, 2017. "Agency CMBS has become a recognized asset class, led by Fannie Mae DUS MBS. We issued more than $55 billion in multifamily MBS last year, plus another $10 billion in GeMS new issuance - significantly more than any other securitized multifamily platform," said Josh Seiff, Fannie Mae's Vice President of Capital Markets and Trading. "FNA 2017-M1 continued the trend - more than 40 investors were involved in the deal, which included 111 loans and was just over $1.0 billion in size. We're looking forward to another market-leading year for the Fannie Mae DUS platform in 2017."

Paladin Energy Ltd (OTC: PALAF) is a uranium production company with projects currently in Australia and two mines in Africa with a strategy to become a major uranium mining house. Since 1998, during a period of sustained downturn in global uranium markets, Paladin accumulated a quality portfolio of advanced uranium projects each having production potential. The Langer Heinrich Mine in Namibia is Paladin's flagship project. The Company has completed a Stage 3 expansion and is now producing at a 5.2Mlb per annum rate. The Kayelekera Mine in Malawi, the Company's second mine, provided an excellent follow-up to Langer Heinrich.

In an upcoming clinical trial by biotech company, PharmaCyte Inc. (OTCQB: PMCB), will consist of patients who have inoperable pancreatic cancer that has not yet spread from the pancreas where it first started to any other place in the body. Patients must also have tumors that no longer respond to the combination chemotherapy treatment of Abraxane® plus gemcitabine after they've been on that treatment for a period of between 4 and 6 months. The company's new trial design calls for multiple cycles of ifosfamide to be given to those patients being treated with PharmaCyte's pancreatic cancer therapy. This will continue until the patients' tumors no longer respond to PharmaCyte's therapy or until treatment-related toxicity accumulates to unacceptable levels.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com has been compensated a total of twenty one thousand dollars for financial news dissemination and pr services by a third party non affiliate for cell medx corp. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com